TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06585410: A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC)

Sponsor: Regeneron Pharmaceuticals · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 369 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$20,009,220

Rescue Site Savings

+$13,186,404

Unlock Full NCT06585410 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06585410 Rescue Dossier →